| Trial ID: | L0252 |
| Source ID: | NCT01204528
|
| Associated Drug: |
Zemplar
|
| Title: |
Vitamin-D Receptor Activation (VDRA) in Chronic Kidney Disease
|
| Acronym: |
SOLID
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Chronic Kidney Disease
|
| Interventions: |
DRUG: Zemplar
|
| Outcome Measures: |
Primary: A significant reduction in muscle sympathetic nerve activity (MSNA) measured by means of microneurography., Sympathetic activation is closely related to severity and progression of cardiovascular diseases, and renovascular dysfunction. We will directly measure sympathetic activation using microneurography (muscle sympathetic nerve activity; MSNA), expressed as bursts/minute and bursts/100 RR-interval. As this is a physiological study, the primary outcome will constitute a significant reduction in MSNA., Measured after 12 weeks treatment. | Secondary: Microcirculatory function measured by laser doppler methods., Assessed by skin laser-doppler methodology, and directly by nailfold capillaroscopy., Measured after 12 weeks treatment.
|
| Sponsor/Collaborators: |
Sponsor: Danderyd Hospital | Collaborators: Abbott
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2|PHASE3
|
| Enrollment: |
36
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: QUADRUPLE (PARTICIPANT, CARE_PROVIDER, INVESTIGATOR, OUTCOMES_ASSESSOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2010-09
|
| Completion Date: |
2013-07
|
| Results First Posted: |
|
| Last Update Posted: |
2013-09-05
|
| Locations: |
Karolinska Institute at Danderyd University Hospital, Danderyd, Stockholm, 18288, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT01204528
|
